RIGL
BULLISH
$32.43
Live
Rigel Pharmaceuticals, Inc. · NASDAQ
Target $51.2
(+57.9%)
$16.43
52W Range
$52.24
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 18, 2026
Market cap
$599.31M
P/E
1.66
ROE
185.9%
Profit margin
124.7%
Debt/Equity
0.14
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
RIGL exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt profile (Debt/Equity 0.14). The company is severely undervalued, trading at $32.43, which is significantly below both its Graham Number ($96.8) and its growth-based intrinsic value ($574.66). While technical trends and insider sentiment are currently bearish, the explosive earnings growth (1598.7% YoY) and a P/E ratio of 1.66 suggest a massive valuation gap. The transition from historical losses to consistent earnings beats indicates a successful pivot to profitability.
Key Strengths
Extreme undervaluation with a P/E of 1.66 and Price/Book of 1.52
Strong financial health indicated by a Piotroski F-Score of 7/9
Explosive earnings growth (1598.7% YoY) and consistent earnings beats
Very low leverage with a Debt/Equity ratio of 0.14
Strong liquidity with a Current Ratio of 2.42
Key Risks
Bearish technical trend (0/100) suggesting short-term price pressure
Negative insider sentiment with recent selling activity
Potential for non-recurring gains inflating the reported profit margin (124.72%)
High volatility inherent to the biotechnology sector
Lack of dividend yield for income-seeking investors
AI Fair Value Estimate
Based on comprehensive analysis
$96.8
+198.5% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
70
Strong
98
90
75
88
0
AI Verdict
Strong Value Play
Key drivers: Extreme P/E compression, Piotroski health score, Massive earnings acceleration
Confidence
90%
Value
98/100
Ref P/E 1.66, Graham Number $96.8
Positives
- P/E of 1.66 is exceptionally low
- Price is ~66% below Graham Number
Watchpoints
- Market has not yet priced in the earnings growth
Future
90/100
Ref YoY Earnings Growth 1598.7%
Positives
- Revenue growth of 21.2%
- Triple-digit EPS growth
Watchpoints
- Biotech pipeline risks
Past
75/100
Ref 25-quarter earnings track record
Positives
- Successful transition from loss-making to profitable
Watchpoints
- Historical volatility in EPS
Health
88/100
Ref Piotroski F-Score, Current Ratio 2.42
Positives
- Piotroski F-Score 7/9
- Low Debt/Equity 0.14
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$32.43
Analyst Target
$51.2
Upside/Downside
+57.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RIGL and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals, Inc.
Primary
|
-6.8% | +165.8% | +92.5% | +16.1% | +27.5% | +11.1% |
|
ESPR
Esperion Therapeutics, Inc.
Peer
|
-91.3% | +70.1% | +119.8% | -9.3% | -23.4% | -10.7% |
|
BVS
Bioventus Inc.
Peer
|
-36.8% | +662.1% | +6.9% | +32.9% | +2.7% | -3.2% |
|
IRWD
Ironwood Pharmaceuticals, Inc.
Peer
|
-64.3% | -66.3% | +259.4% | +128.3% | -1.4% | +2.5% |
|
AVNS
Avanos Medical, Inc.
Peer
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
RIG
Rigel Pharmaceuticals, Inc.
Primary
5Y
-6.8%
3Y
+165.8%
1Y
+92.5%
6M
+16.1%
1M
+27.5%
1W
+11.1%
ESP
Esperion Therapeutics, Inc.
Peer
5Y
-91.3%
3Y
+70.1%
1Y
+119.8%
6M
-9.3%
1M
-23.4%
1W
-10.7%
BVS
Bioventus Inc.
Peer
5Y
-36.8%
3Y
+662.1%
1Y
+6.9%
6M
+32.9%
1M
+2.7%
1W
-3.2%
IRW
Ironwood Pharmaceuticals, Inc.
Peer
5Y
-64.3%
3Y
-66.3%
1Y
+259.4%
6M
+128.3%
1M
-1.4%
1W
+2.5%
AVN
Avanos Medical, Inc.
Peer
5Y
-72.6%
3Y
-56.0%
1Y
-17.1%
6M
+9.0%
1M
+14.8%
1W
+6.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
1.66
Forward P/E
6.76
PEG Ratio
N/A
P/B Ratio
1.52
P/S Ratio
2.04
EV/Revenue
1.69
EV/EBITDA
3.89
Market Cap
$599.31M
Profitability
Profit margins and return metrics
Profit Margin
124.72%
Operating Margin
33.19%
Gross Margin
82.02%
ROE
185.94%
ROA
23.15%
Growth
Revenue and earnings growth rates
Revenue Growth
+21.2%
Earnings Growth
+1598.7%
Q/Q Revenue Growth
+21.19%
Q/Q Earnings Growth
+1769.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.14
Low debt
Current Ratio
2.42
Strong
Quick Ratio
2.08
Excellent
Cash/Share
$8.39
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
91.5%
Op. Margin
33.2%
Net Margin
384.0%
Total Assets
$0.5B
Liabilities
$0.1B
Equity
$0.4B
Debt/Equity
0.31x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-03-03
$13.54
+1005.3% surprise
2025-11-04
$1.46
+56.0% surprise
2025-08-05
$3.28
+133.4% surprise
Healthcare Sector Comparison
Comparing RIGL against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
P/E Ratio
1.66
This Stock
vs
89.02
Sector Avg
-98.1%
(Discount)
Return on Equity (ROE)
185.94%
This Stock
vs
-100.15%
Sector Avg
-285.7%
(Below Avg)
Profit Margin
124.72%
This Stock
vs
-13.63%
Sector Avg
-1015.1%
(Weaker)
Debt to Equity
0.14
This Stock
vs
3.22
Sector Avg
-95.8%
(Less Debt)
Revenue Growth
21.2%
This Stock
vs
121.05%
Sector Avg
-82.5%
(Slower)
Current Ratio
2.42
This Stock
vs
4.55
Sector Avg
-46.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals, Inc.
|
BULLISH | $599.31M | 1.66 | 185.9% | 124.7% | $32.43 | |
|
ESPR
Esperion Therapeutics, Inc.
|
NEUTRAL | $598.37M | - | -% | -5.6% | $2.33 | Compare |
|
BVS
Bioventus Inc.
|
BEARISH | $595.53M | 26.79 | 13.2% | 4.0% | $8.84 | Compare |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
BEARISH | $591.9M | 24.2 | -% | 8.1% | $3.63 | Compare |
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | Compare |
RIGL
Rigel...
BULLISH
Mkt Cap
$599M
P/E
1.7
ROE
185.9%
Price
$32.43
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-20 | MOOS WALTER H | Director | Sale | 4,000 | $145,440 |
| 2026-02-20 | MOOS WALTER H | Director | Option Exercise | 4,000 | $96,000 |
| 2026-02-17 | RODRIGUEZ RAUL R | Chief Executive Officer | Stock Award | 53,915 | - |
| 2026-02-17 | SCHORNO DEAN L | Chief Financial Officer | Stock Award | 20,636 | - |
| 2026-02-17 | FUREY RAYMOND J | General Counsel | Stock Award | 19,497 | - |
| 2026-02-17 | SANTOS DAVID A | Officer | Stock Award | 19,430 | - |
| 2026-02-17 | ROJKJAER LISA | Officer | Stock Award | 18,894 | - |
| 2026-01-26 | RODRIGUEZ RAUL R | Chief Executive Officer | Option Exercise | 80,000 | $2,192,000 |
| 2025-12-22 | SCHORNO DEAN L | Chief Financial Officer | Option Exercise | 6,500 | $139,786 |
MOOS WALTER H
Director
2026-02-20
4,000 shares
·
$145,440
MOOS WALTER H
Director
2026-02-20
4,000 shares
·
$96,000
RODRIGUEZ RAUL R
Chief Executive Officer
2026-02-17
53,915 shares
SCHORNO DEAN L
Chief Financial Officer
2026-02-17
20,636 shares
FUREY RAYMOND J
General Counsel
2026-02-17
19,497 shares
SANTOS DAVID A
Officer
2026-02-17
19,430 shares
ROJKJAER LISA
Officer
2026-02-17
18,894 shares
RODRIGUEZ RAUL R
Chief Executive Officer
2026-01-26
80,000 shares
·
$2,192,000
SCHORNO DEAN L
Chief Financial Officer
2025-12-22
6,500 shares
·
$139,786
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
8-K
10-K
8-K
8-K
10-Q
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
5 analysts
Jefferies
2025-11-05
Hold
Buy
Cantor Fitzgerald
2025-11-05
Neutral
Neutral
Past News Coverage
Recent headlines mentioning RIGL from our newsroom.
Newest → oldest
No matching news yet.